Ovarian

Antihypertension Drug Losartan May Improve Treatment Of Ovarian Cancer

(MGH) Jan 15, 2019 - A new study from a Massachusetts General Hospital (MGH) research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer.

read press release

New AI ‘Shapeshift’ Test Identifies Women With ‘Very High Risk’ Ovarian Cancer

(ICR [UK]) Jan 12, 2019 - Scientists have developed a new test that scans the shapes of tumour cells to pick out women with especially aggressive ovarian cancer, so treatment can be tailored to their needs.

read article

CNIO Researchers Confirm Links Between Aggressive Prostate Cancer And Hereditary Breast Cancer

(CNIO [Madrid, Spain]) Jan 9, 2019 - Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others. The finding was confirmed in a study, published in the Journal of Clinical Oncology, led by Elena Castro, Nuria Romero-Laorden and David Olmos, from the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO). It reveals that family members of patients with prostate cancer who carry BRCA2 and DNA-repair gene mutations have an increased risk of developing cancer and should be evaluated in familial cancer prevention programmes. Furthermore, the new study shows that prostate cancer in men with BRCA2 mutations is associated with worse outcomes and poor responses to standard treatments. Researchers are currently assessing the benefits of ovarian and breast cancer therapies for prostate cancer patients.

read article

Moderna Stock Pops 4.2% on Clinical Update

(BioSpace) Jan 9, 2019 - Moderna’s clinical and business update at the JP Morgan Healthcare Conference led the newly public company shares to pop 4.2 percent, a welcome change.

read article

BRCA Exchange Aggregates Data On Thousands Of BRCA Variants To Inform Understanding Of Cancer Risk

(NCI) Jan 9, 2019 - A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public.

read press release

Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China

(MarketWatch) Jan 9, 2019 - Zai Lab Limited, a Shanghai-based innovative commercial stage biopharmaceutical company, today announced completion of patient enrollment of its pivotal trial of niraparib (ZL-2306; ZEJULA®) in development for second-line maintenance therapy in patients with recurrent, platinum-sensitive ovarian cancer.

read article

Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives

(Moderna) Jan 8, 2019 - Moderna, Inc. today announced recent updates to several of its immuno-oncology and rare disease programs and outlined its 2019-2020 corporate objectives.

read corporate press release

Ribon Raises $65M to Pursue PARP-Blocking Pills for Cancer

(Xconomy Boston) Jan 4, 2019 - A new class of ovarian and breast cancer drugs that thwart a DNA repair mechanism ushered in a novel approach to treating cancer.

read article

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update On JAVELIN Ovarian 100 Trial Of Avelumab In Previously Untreated Advanced Ovarian Cancer

(Pfizer) Dec 21, 2018 - Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study’s initial hypothesis, and therefore the alliance made the decision to terminate the trial in alignment with the independent Data Monitoring Committee. The alliance between Merck KGaA, Darmstadt, Germany – which operates its biopharmaceutical business as EMD Serono in the US and Canada – and Pfizer was the first to test an immunotherapy in this indication, given the significant unmet need in the treatment of ovarian cancer. Four out of five women with ovarian cancer are diagnosed at advanced stages.1 Most women with advanced ovarian cancer ultimately die within five years due to refractory, resistant or recurrent disease.

read corporate press release

Yale Cancer Center Researchers Find Genetic Explanations Behind The Rapid Spread Of Ovarian Cancer

(Yale Cancer Center) Dec 24, 2018 - In a breakthrough study, Yale Cancer Center (YCC) researchers have defined the genetic characteristics of primary, metastatic and recurrent ovarian tumors and evaluated new targeted therapies to treat the disease.

read article

Johnson & Johnson Loses Bid to Overturn a $4.7 Billion Baby Powder Verdict

(New York Times) Dec 19, 2018 - Johnson & Johnson lost its motion on Wednesday to reverse a jury verdict that awarded $4.69 billion to women who blamed their ovarian cancer on asbestos in the company’s baby powder and other talc products.

read article

Lynparza Approved by US FDA for 1st-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer

(AstraZeneca) Dec 19, 2018 - AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy, as detected by an FDA-approved companion diagnostic test. This is the first regulatory approval for a PARP inhibitor in the 1st-line maintenance setting for BRCAm advanced ovarian cancer. The approval was based on positive results from the pivotal Phase III SOLO-1 trial in which Lynparza reduced the risk of disease progression or death by 70 percent in patients with BRCAm advanced ovarian cancer who were in complete or partial response to platinum-based chemotherapy (HR 0.30 [95% CI 0.23-0.41], p<0.0001) compared to placebo following platinum-based chemotherapy. The safety profile of Lynparza was consistent with previous trials.

read corporate press release

Lynparza Meets Primary Endpoint In Phase III SOLO-3 Trial For The Treatment Of Relapsed BRCA-Mutated Advanced Ovarian Cancer

(AstraZeneca) Dec 20, 2018 - AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced positive results from the randomised, open-label, controlled, Phase III SOLO-3 trial of Lynparza (olaparib) tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment. The trial was conducted as a post-approval commitment in agreement with the US Food and Drug Administration (FDA). This is the fourth Phase III trial to demonstrate a positive result for Lynparza. AstraZeneca and MSD now plan to discuss these results with the FDA. Results from the trial showed BRCA-mutated (BRCAm) advanced ovarian cancer patients treated with Lynparza following two or more prior lines of chemotherapy demonstrated a statistically-significant and clinically-meaningful improvement in the primary endpoint of objective response rate (ORR) and the key secondary endpoint of progression-free survival (PFS) compared to chemotherapy. The safety and tolerability profile of Lynparza was consistent with previous trials.

read corporate press release

Lynparza Gets FDA Approval for Ovarian Cancer

(PharmaTimes [UK]) Dec 20, 2018 - AstraZeneca and MSD have announced that Lynparza (olaparib) has been given the green light by the FDA for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer, further expanding the drug's reach. The decision rides on the back of Phase III data showing that in this setting Lynparza reduced the risk of disease progression or death by 70%, compared to placebo. The SOLO-1 trial also found that 60% of patients receiving Lynparza remained progression-free at three years compared to 27% of the placebo group.

read article

AstraZeneca: Ovarian Cancer Drug Meets First Goals

(MarketWatch) Dec 20, 2018 - AstraZeneca PLC's Lynparza drug met its primary goal in a clinical trial for treatment of relapsed ovarian cancer, the pharmaceutical company said Thursday.

read article

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer

(Myriad Genetics) Dec 19, 2018 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with advanced ovarian cancer who have a germline BRCA mutation (gBRCAm) and are eligible for first-line maintenance therapy with AstraZeneca’s PARP (poly ADP ribose polymerase) inhibitor, Lynparza® (olaparib) following response to platinum-based chemotherapy. “We congratulate AstraZeneca and Merck on obtaining FDA approval of Lynparza for patients with BRCAm advanced ovarian cancer, and we are excited to expand the use of BRACAnalysis CDx as the companion diagnostic test in this population,” said Lloyd Sanders, president, Myriad Oncology. “We estimate there are more than 20,000 patients newly diagnosed with ovarian cancer in the United States every year who qualify for a BRACAnalysis CDx test.”

read corporate press release

CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca® (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer

(Yahoo! Finance) Dec 13, 2018 - European Commission (EC) marketing authorization is anticipated Q1 2019.

read article

IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress

(Markets Insider) Dec 13, 2018 - IMV Inc. today announced that investigators shared new positive data from the company’s ongoing DeCidE1 (DPX-Survivac with low dose CyclophosphamIDe and Epacadostat) clinical trial at the 2018 ESMO Immuno-Oncology Congress.

read article

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

(Markets Insider) Dec 11, 2018 - Aravive, Inc. today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer.

read article

This Cancer Biotech Stock Just Averted A Patent Disaster In Europe

(Investor’s Business Daily) Dec 4, 2018 - Clovis Oncology stock surged Tuesday after a European patent decision averted a "worst case" scenario for its ovarian cancer treatment, Rubraca.

read article
Next Page